Computationally restoring the potency of a clinical antibody against SARS-CoV-2 Omicron subvariants.

ABSTRACT: The COVID-19 pandemic underscored the promise of monoclonal antibody-based prophylactic and therapeutic drugs^1-3, but also revealed how quickly viral escape can curtail effective options^4,5. With the emergence of the SARS-CoV-2 Omicron variant in late 2021, many clinically used antibody drug products lost potency, including Evusheld^™ and its constituent, cilgavimab^4,6. Cilgavimab, like its progenitor COV2-2130, is a class 3 antibody that is compatible with other antibodies in combination⁴ and is challenging to replace with existing approaches. Rapidly modifying such high-value antibodies with a known clinical profile to restore efficacy against emerging variants is a compelling mitigation strategy. We sought to redesign COV2-2130 to re

SUBMITTER: Desautels TA 

PROVIDER: S-EPMC9628197 | biostudies-literature | 2023 Apr

REPOSITORIES: biostudies-literature